DWTX
Dogwood Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.29
−2.14%Aug 13, 2026, 12:30 UTC
Dogwood Therapeutics announced its financial results for the second quarter of 2026.
Source:Jul 20, 2026, 12:30 UTC
Dogwood Therapeutics enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial for Halneuron to treat chemotherapy-induced neuropathy.
Source: